Winning all six core categories and three champion ratings validates Vetter as a trusted partner

Vetter's high-level performance further substantiates its dedicated performance in customer-critical services

Results affirm the approach, vision, and strategy of the company's daily work for customers

High ranking is further affirmation of customer experiences in working with Vetter as a strong and reliable partner

RAVENSBURG, GERMANY  - 3 March 2022 - Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), won the 2022 CMO Leadership Awards in all six core categories - quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award, now in its eleventh year, was given by the leading trade press publication, Life Science Leader. Due to the ongoing Covid-19 pandemic, the awards ceremony will be held virtually beginning of March.

"Our result this year is an unprecedented achievement for Vetter and represents a landmark victory for the company," said Vetter Managing Director Peter Soelkner. "To win in all six categories is exceptional in its own right. However, to be awarded Champion in the areas of Compatibility, Quality and Expertise is particularly rewarding and reflects the day-to-day dedication and hard work of our 5,700 employees on three continents." C arsten Press, Vetter's Senior Vice President Key Account Management/Supply Chain Management/Marketing added, "Without doubt, this achievement firmly demonstrates that we continuously strive to meet or even exceed our global customers' expectations. The awards mirror our partnership approach to be a trusted source for producing life-critical medications for patients in need."

The CMO Leadership Awards program is unique among other industry awards since winners are chosen according to customer evaluations of the service providers they have actually worked with in the past 18 months. Thus, results cannot be influenced in any manner and are truly representative of actual customer performance.

"For nearly a decade, these awards have proven most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, Industry Standard Research (ISR), which only surveys drug sponsors who have worked recently with specific CDMOs, ensures the validity of these results. Our winners will be your champions of outsourcing," said Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. (*).